Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services.